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A B S T R A C T
The diagnosis and staging of acute cholecystitis, upon a lot of diagnostic methods and some scoring systems, is still
a great clinical problem. The aim of the study was to investigate if serum Troponin I is elevated in patients with acute
cholecystitis. Following informed consent, 65 patients with clinical and laboratory signs of acute cholecystitis were
enrolled. All patients had measured serum Troponin I level and an abdominal ultrasound was done before definitive
treatment was performed. Increased serum Troponin I level was found in most patients with severe form of acute
cholecystitis (p<0.00001). It reached sensitivity of 94.5% and specificity of 57.1% of this test. In multiple regression
analysis Troponin I significantly correlated (p<0.05) with the serum aspartate aminotransferase (r=0.27), gamma-
-glutamyl transferase (r=0.25) and gallbladder wall (>6 mm) thickness (r=0.58). Our study confirms that in most
patients with severe and acute cholecystitis, serum Troponin I is increased. Troponin I level is in a lower range than it
would be in patients with cardiac muscle damage or necrosis. Measuring serum Troponin I is a fast, reliable and
widely performed test that could, with other routinely measured parameters, help in early diagnosis of the severe form
of acute cholecystitis.
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Introduction
The diagnosis of acute cholecystitis is, in most cases, a
straight forward task. On the contrary, the predictability
of its complications and severity of disease for everyday
practice is still a challenge. A new and improved algo-
rithm is necessary and important, because the intro-
duction of timely and appropriate therapy is essential1,2.
Other authors have attempted to resolve this problem by
utilizing various other parameters, such as: leukocytosis,
right upper quadrant (RUQ) tender mass, elevated body
temperature, elevated serum level of liver function enzy-
mes, the presence of pericholecystitic fluid, fluid in the
abdominal cavity, presence of acute pancreatitis, and high-
er blood flow velocity in the gallbladder wall on Doppler
imaging, among other3–8. Introduction of the APPACHE
II score for intensive care patients with acute cholecysti-
tis improved outcome prediction and disease severity de-
termination6,7. Finally, the Tokyo guidelines included
parameters that represented the local status of inflam-
mation and systemic response to acute cholecystitis, de-
pending on disease severity like hypoxia and circulation6,9.
We studied Troponin I as one potentially easily measu-
rable and widely performed test that can help in the early
diagnose of the severe form of acute cholecystitis which
can then be promptly and more aggressively treated.
Significantly elevated Troponin I level (>0.5 ng/mL) re-
presents a myocardial hypoxia and infarction but non-
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-specific elevation of Troponin I (<0.5 ng/mL) is a sign of
myocardial hypoxia but not infarction3,10,11–15. By measur-
ing Troponin I in combinations with gallbladder wall
thickness, we attempted to make the detection of disease
severity more precise and widely applicable. Measure-
ment of Troponin I is simple, precise and available in
most laboratories which make it a practical parameter to
be incorporated into everyday practice.
Materials (Patients) and Methods
Materials (patients)
All investigations were done and all specimens were
collected from the 65 subjects upon their written in-
formed consents, according to the Helsinki Declaration
and the approval of Hospital Ethics Committee.
In 65 patients with acute cholecystitis we measured
the Troponin I (cTnI) level. Acute cholecystitis was diag-
nosed by standard clinical, laboratory and ultrasound
based signs and symptoms1,3,9. The severity assessment
of acute cholecystitis was done according to Tokyo guideli-
nes1,9. The criteria for moderate cholecystitis was local and
systemic signs of inflammation, leucocytes >18.00/mm3,
palpable tender mass in the right upper abdominal qua-
drant, duration of complaints more than 72 hours, mark-
ed local inflammation (biliary peritonitis, pericholecys-
titis, abscess, hepatic abscess, gangrenous cholecystitis,
emphysematous cholecystitis)1. The criteria for severe
cholecystitis was that the severe acute cholecystitis was
accompanied by dysfunction in any one of the following
organs or systems: cardiovascular dysfunction (hypoten-
sion requiring treatment with dopamine >5 mg/kg per
minute, or any dose of doputamine), neurological dysfunc-
tion (decreased level of of consciousness), respiratory
dysfunction (PaO2 /FiO2 ratio <300), renal dysfunction
(olyguria, elevated creatinine), hepatic dysfunction (Pro-
trombine time-INR>1.5), hematological dysfunction1.
Methods
Inclusion criteria
Clinical symptoms of acute cholecystitis in all pa-
tients were upper right quadrant pain 1–2 hours after a
meal, which propagates towards the scapula and back in
association with elevated body temperature1,3,4,9. Labora-
tory signs were high leukocyte count and elevated serum
C-reactive protein value (CRP). Beside a significantly
elevated leukocyte count and the duration of symptoms
for more than 24 hours, patients with severe form of
acute cholecystitis had a palpable abdominal mass in
right upper quadrant. Abdominal ultrasound findings of
acute cholecystitis, according to standard criteria, were
thickness of the gallbladder wall more than 4 mm with
signs of dissection4. The gallbladder wall measurements
were made on its front wall and by two experienced
ultrasonographers in random fashion. We also checked
for presence of pericholecystic fluid1,3,9.
Exclusion criteria
Patients with an acute coronary incident were exclud-
ed from the study on clinical ground, non revealing ECG,
serum values of creatine kinase and its MB fraction3,9.
Furthermore, all studied patients with mild and severe
acute cholecystitis were tested for coronary artery disease
by treadmill stress test two months after acute cho-
lecystitis was healed3. Only patients that were negative
for both, acute coronary syndrome and cardiac stress test
were included in the study. Renal function was measured
by serum creatinine and urea values1,3,9. Only patients
with normal findings were included while patients with
renal failure were excluded from the study. Excluded
were also patients with biliary obstruction1,3,9. An ob-
struction was detected by abdominal ultrasound with
common biliary duct measuring more than 7 mm, elevat-
ed serum values of bilirubin, gamma-glutamyl trans-
peptidase and alkaline phosphatase3,9. Excluded from the
study were also patients with complications such as
acute pancreatitis or ileus. Upper gastrointestinal endos-
copy was done to exclude all other differential diag-
noses3. Up to two months after an episode of severe acute
cholecystitis that was conservatively treated and healed,
all patients underwent trans-abdominal or laparoscopic
surgical cholecystectomy1,3,9. Gallbladder tissue sample
analysis was done according to standard procedure. All
patients with pathological findings that fulfilled inclusion
criteria were included in the study while other causes of
gallbladder diseases were excluded (e.g. tumor, etc.).
The Troponin I measurements
The Troponin I serum values were measured by im-
munoflorometric method (Dimension, Dade Boehringer).
We considered Troponin I values up to 0.5 ng/mL while
those values between 0.5–1.5 ng/mL were excluded as a
possible acute myocardial infarction3.
Other measurements
In our studies we used ultrasound system with convex
3.5 MHz probe. All laboratory parameters (leukocyte,
CRP, amylase, bilirubin, aspartate aminotransferase, ala-
nin aminotransferase, gamma-glutamyl transpeptidase,
alkaline phosphatase, urea and creatinine) were measur-
ed according to standard procedures.
Statistics
We used software STATISTICA 2.1 for statistical ana-
lyses that included mean, standard deviation, ANOVA,
test of homogeneity of variance and multivariate multi-
ple regression test, and logistic regression. We calculated
accuracy etc. by using ROC analysis.
Results
Enrolled patients were divided into two groups, mod-
erate (N=18) or severe (N=47). Most patients with severe
acute cholecystitis have increased serum level of Tropo-
nin I. The patients with severe acute cholecystitis had
significantly elevated leucocyte count, CRP, Tropinin,
serum amylase level and had presence of pericholecy-
stitis (p<0.05; Levene test of Homogeneity) (Table1). We
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have found no statistical difference between other para-
meters according to the Tokyo assessment of disease se-
verity.
We had 35 out of 47 patients with Troponin I values in
the range of 0.05–0.5 ng/mL (Table 2). No elevation of
Troponin I above 0.5 ng/mL was measured. In the group
of patients with the moderate form of disease, Troponin I
was at level 0.00 ng/mL in 16 patients and two were
above 0.00 ng/mL (Table 1). The Troponin I serum level
reached sensitivity level of 94%, specificity of 57%, false
positive value of 5.4%, and accuracy of 78.4%.
Troponin I, calculated by multiple regression analy-
sis, significantly correlated with increase of gallbladder
wall thickness (p<0.001; multiple regression). Not sur-
prisingly, a significant correlation was also seen with
Troponin I and aspartate aminotransferase (p<0.03; mul-
tiple regression) and also with Troponin I and gam-
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TABLE 1
THE MEANS AND RANGES OF PARAMETERS ACCORDING TO TOKYO CLASSIFICATION OF DUSEASE SEVERITY IN PATIENTS WITH
ACUTE CHOLECYSTITIS
Moderate (score=2) Severe (score=3)
Median Range Median Range p
Age (yrs.) 64.6 37 60.7 47.0 0.539
Sex (m/f) 1.77 1.0 1.7 1.0 0.199
Leucocytes (´109/L) 12.54 12.7 14.6 13.0 0.0284
CRP (mg/L) 19.8 37.7 49.5* 233 0.0002
Troponin I (mg/L) 0.004 0.05 0.22* 0.48 0.0001
US gallbladder wall thickness (mm) 5.5 5.0 6.36 4.0 0.011
US/pericholecystitis (y/n) 0.16 1.0 0.27* 1.0 0.046
CK (U/L) 65.8 82.0 81.1 135.0 0.478
Bilirubin (mmol/l) 14.4 28.0 16.6 31.3 0.131
AST (U/L) 21.1 31.0 26.4 37.0 0.451
ALT (U/L) 21.5 34.0 23.1 34.0 0.767
GGT (U/L) 33.3 58.0 45.1 112.0 0.171
ALP (U/L) 71.0 80.0 67.0 85.0 0.066
Amylase – s (U/L) 69.10 88.0 63.6* 122.0 0.028
Amylase – u (U/L) 131.1 200.0 143.0 264.0 0.518
* Statistical significance for Troponin I was at *p<0.05 level (Levene test of Homogeneity). Legend: CRP: C-reactive protein, AST:
aspartate aminotransferase, ALT: alanine aminotransferase, GGT: gamma-glutamyl transpeptidase, ALP: alkaline phosphatase, Amy-
lase-s: amylase serum level, amylase-u: amylase in urine, CK: creatine kinase.
TABLE 2
RESULTS OF SERUM TROPONIN I VALUES IN PATIENTS WITH
EITHER MODERATE OR SEVERE FORM OF ACUTE
CHOLECYSTITIS
Moderate (N) Severe (N) Total (N)
Troponin = 0 ng/mL 16 12 28
Troponin > 0 ng/mL 2 35 37
18 47 65
Result of c2-test presents statisticaly significant diference (p<
0.005; with c2=21.26 and df=1) between the group with troponin
level 0.00 ng/mL vrs. the group with troponin level higher than
0.00 ng/mL.
TABLE 3







r p r p
Age 0.04 0.77 –0.07 0.60
Sex 0.16 0.21 –0.10 0.44
Leucocytes 0.14 0.26 –0.03 0.79
CRP 0.42* 0.001 0.10 0.42
TROPONIN 0.58* 0.001 / /
US/Gallbladder
thickness (>6 mm)
/ / 0.58* 0.001
US/pericholecystitis 0.16 0.213 0.05 0.68
CPK –0.12 0.33 –0.03 0.81
Bilirubin 0.13 0.31 0.08 0.52
AST 0.09 0.48 0.27* 0.03
ALT 0.04 0.76 0.17 0.18
GGT 0.22 0.079 0.26* 0.048
ALP –0.01 0.96 –0.15 0.23
Amylase (serm.) 0.05 0.68 0.10 0.42
Amylase (urine) 0.08 0.53 0.10 0.41
Statistical significance was at *p<0.05 leve (Multiple regresion
analysis). Legend: CRP: C-reactive protein, AST: aspartate ami-
notransferase, ALT: alanine aminotransferase, GGT: gamma-glu-
tamyl transpeptidase, ALP: alkaline phosphatase, Amylase-s: amy-
lase serum level, amylase-u: amylase in urine, CK: creatine kinase.
ma-glutamyl transferase (p<0.048; multiple regression)
(Table 3). Gallbladder wall thickness significantly corre-
lated with CRP (p<0.001; multiple regression).
Logistic regression analysis for severity of cholecys-
titis, according to the all parameters, found proportion of
variance accounted for =.8463 and R=0.919 with vari-
ance explained of 84.634%. Testing observed versus pre-
dicted values, observed values were 0.099+0.9001* pre-
dicted values, with correlation r=0.9282 at regression of
95% confidence.
Test of variance of homogeneity detected highly sta-
tistically significant difference when comparing the pa-
tients with US measures gallbladder wall thickness <6
mm with the patients with >6 mm, in the Troponin I
level (p<0.00001), in CRP level (p<0.00028), serum am-
ylase level (p<0.006), presence of pericholecystitic fluid
(pericholecystitis) (p<0.046) and patients age (p<0.06).
We found no statistical significant difference by this test
between other parameters (Table 4).
Discussion
The Tokyo guidelines recognize three degrees of acute
cholecystitis. In the first, the disease is only localized to
the gallbladder. The second degree is described with ill-
ness in the surrounding tissues but the patient is without
systemic complications and operative therapy has higher
risk. The third degree represents systemic complications
such as high leukocyte count, abdominal palpable mass,
and illness duration for more than 24 hours6. Similar cri-
teria that include C-reactive protein, pericholecystitic fluid
or gallbladder thickness detectable by ultrasound, were
historically used for better assessment1–4,6,9.
Our results in the majority of patients with a severe
form of acute cholecystitis showed elevated serum levels
of Troponin I. On the contrary, patients with the mild
form of the disease had no detectible level of Troponin I.
Troponin I has high sensitivity (94%) and much lower
specificity (57 %) for severe cholecystitis with only 5.4%
of false positive results (Table 2). All measured serum
Troponin I levels in patients with the severe form of
cholecystitis were in a lower range than for patients with
acute myocardial infarction or acute coronary syndrome.
A literature search found other medical conditions that
can lead to a false positive rise in Troponin I levels and
possible to a misdiagnosis. Congestive heart failure, sepsis,
muscular activity, pulmonary embolism, supraventricu-
lar tachycardia, arterial hypertension all can lead to a rise
in serum Troponin I levels also in the intervals that are
non characteristic for acute myocardial infarction11–18.
Authors explain that in this conditions elevation of Tro-
ponin I (and Troponin T) is due to cholecystitis itself or
the systemic inflammation, which may have been as-
sociated with transient bacteraemia despite the negative
blood cultures, and led to release of troponin from the
myocardium16–18. Meta analysis presents that the eleva-
tion of Troponin T is positively related to higher mor-
tality, but the meta analysis results, for the elevation of
Troponin I is unclear, largely because of the lack of
standardization of assays18–20.
Literature gives us some other theoretical explana-
tions for noncardial elevation of Troponine I. Local and
circulating inflammatory markers including tumor ne-
crosis factor a, interleukin 6 and reactive oxygen species,
as well as bacterial endotoxins, may lead to direct myocar-
dial injury by cytotoxic effects19. Moreover, elevated cTn
values provide prognostic information and the extent of
cTn elevation seems to correlate with the severity of the
disease process19.
Other parameters can be used in the detection of dis-
ease severity such as body temperature, leukocytosis, C-re-
active protein, transferrin, and alpha 1-antitripsin6,21,22.
Reasons for elevation of these parameters in acute cho-
lecystits is well known, as it is well known that this pa-
rameters are more elevated in severe than in the mild
form of acute cholecystitis, and it is no need to explain it
now1,3,9. But we have to explain that the elevation of
these parameters is associated with the elevation of
Troponin I in acute cholecystitis. The reasons of Tro-
ponin I elevation mentioned above, are similar to the rea-
sons for elevation of this parameters as are leucocyte,
CRP, etc. When Troponin I was compared in multiple re-
gression analysis with other parameters, we found a sig-
nificant correlation with the increased gallbladder thick-
ness, the aspartate aminotransferase and the gamma-
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TABLE 4
THE DIFFERENCES BETWEEN THE PARAMETERS ACORDONG
TO ULTRASOUND MEASURED GALLBLADDER WALL





<6 X±SD >6 XSD p
Age (yrs.) 58±9 63±13 0.067
Sex 1.66±0.4 1.74± 0.257
Leucocytes (x109/L) 14±4.45 14± 0.115
CRP (mg/L) 22±11 48±	 0.00028
Troponin I (ug/L) 0.033±0.09 0.21±
	 0.00001
US/pericholecystitis (y/n) 0.17± 0.27±0.45 0.046
CK (U/L) 80± 76±28 0.078
Bilirubin (mmol/l) 17± 167 0.531
AST (U/L) 22± 269 0.445
ALT (U/L) 20± 239 0.657
GGT (U/L) 35± 4422 0.368
ALP (U/L) 65± 6922 0.678
Amylase-s (U/L) 58± 7238 0.006
Amylase-u (U/L) 134± 14263 0.483
Statistical significance for Troponin I was at *p<0.0001 level (Ana-
lysis of variance). Legend: CRP: C-reactive protein, AST: aspartate
aminotransferase, ALT: alanine aminotransferase, GGT: gamma-
-glutamyl transpeptidase, ALP: alkaline phosphatase, Amylase-s:
amylase serum level, amylase-u: amylase in urine, CK: creatine
kinase.
-glutamyl transpeptidase, parameters that represent
liver and biliary injury (Table 3). Increased gallbladder
wall thickness of 6 mm or more has the best correlation,
at very high and statistically significant level with Tro-
ponin I (p<0.0001) and CRP (Table 4). CRP has been al-
ready described in the literature and in the Tokyo guide-
lines as a borderline parameter of statistical significance
to distinguish between mild and severe forms of the
disease1,6,22,23.
Taken together, the determination of Troponin I in
conjunction with gallbladder wall thickness, other param-
eters (leukocyte count, CRP, aspartate aminotransferase
gamma-glutamyl transpeptidase etc.) and clinical presen-
tation could be a very sensitive, useful and simple tool,
easily incorporated into daily practice. Clinically, it is
very important to determine the degree of acute and non
obstructive cholecystitis (mild or severe form, with or
without complications). This can lead to a more precise
determination of disease severity ensuring timely and
appropriate therapy resulting in lower costs and fewer
complications.
Conclusion
We can conclude that the measurement of Troponin I
level in acute cholecystitis patients, can improve medical
decision making in the field of diagnosis, severity disease
assessment, and therapy.
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KVANTITATIVNA ANALIZA SERUMSKOG TROPONINA I U BOLESNIKA S AKUTNOM UPALOM
@U^NJAKA
S A @ E T A K
Dijagnozu i stupnjevanje akutne upale `u~njaka i dalje je, unato~ brojnim dijagnosti~kim metodama, ostao te`ak
zadatak. Cilj ovog rada bio je istra`iti ulogu povi{enih serumskih vrijednosti Troponina I u bolesnika s akutnim kole-
cistitisom. Nakon informiranog pristanka u studiju smo uklju~ili 65 bolesnika s klini~kim i laboratorijskim znakovima
akutne upale `u~njaka. Svim bolesnicima je mjerena razina serumskog Troponina I te im je u~injen i transabdominalni
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ultrazvuk prije po~etka lije~enja. U ve}ine bolesnika s te{kim oblikom akute upale `u~njaka na|ene su povi{ene vrijed-
nosti Troponina I (p<0,00001). Postigli smo osjetljivost testa od 94,5% i specifi~nost testa od 57,1%. Testom multiple
regresije statisti~ki zna~ajnija korelacija (p<0,05) postignuta je za Troponin I, za serumsku aspart aminotransferazu
(r=0,27), gamaglutamil transferazu (r=0,25) i za debljinu stjenke `u~njaka (>6 mm) (r=0,58). Na{a studija potvr|uje
da je ve}ina bolesnika s te{kim oblikom akutne upale `u~njaka imala povi{ene vrijednosti Troponina, ali u vrijednosti-
ma koje nisu karakteristi~ne za o{te}enje ili nekrozu sr~anog mi{i}a. Mjerenje Troponina I brza je i {iroko primjenjiva me-
toda koja uz ostale rutinske parametre mo`e pomo}i u dijagnostici i stupnjevanju te{kih oblika akutne upale `u~njaka.
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